Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for AVTR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2018. Start Trial.
Date Value
June 30, 2026 -112.40M
March 31, 2026 -107.20M
December 31, 2025 0.70M
September 30, 2025 -369.60M
June 30, 2025 -6.90M
March 31, 2025 -33.60M
December 31, 2024 -755.30M
September 30, 2024 -198.60M
June 30, 2024 -197.10M
March 31, 2024 -130.20M
December 31, 2023 -184.10M
September 30, 2023 -188.40M
June 30, 2023 -196.20M
March 31, 2023 -275.00M
December 31, 2022 -81.60M
September 30, 2022 -219.40M
June 30, 2022 -220.50M
Date Value
March 31, 2022 -127.20M
December 31, 2021 1.461B
September 30, 2021 980.40M
June 30, 2021 998.80M
March 31, 2021 -221.00M
December 31, 2020 -380.40M
September 30, 2020 -316.10M
June 30, 2020 -13.30M
March 31, 2020 -73.10M
December 31, 2019 -67.40M
September 30, 2019 -172.60M
June 30, 2019 38.30M
March 31, 2019 -106.10M
December 31, 2018
September 30, 2018
June 30, 2018 28.10M
March 31, 2018 -77.80M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Medpace Holdings, Inc. -288.34M
Champions Oncology, Inc. -0.019M
Personalis, Inc. 7.988M
Adaptive Biotechnologies Corp. 142.19M
10X Genomics, Inc. 3.016M